SC TO-I/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE TO

Amendment No. 2

TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) or 13(e)(1) OF

THE SECURITIES EXCHANGE ACT OF 1934

CARDIOME PHARMA CORP.

(Name of Subject Corporation (issuer))

CARDIOME PHARMA CORP. (Issuer)

(Name of Filing Persons (identify status as offeror, issuer or other person))

Common Shares, Without Par Value

(Title of Class of Securities)

14159U202

(CUSIP Number of Class of Securities)

Cardiome Pharma Corp.

Attention: Curtis Sikorsky, Chief Financial Officer

6190 Agronomy Road, 6th floor, Vancouver, British Columbia, Canada V6T 1Z3

(800) 330-9928

(Name, address and telephone number of person authorized to

receive notices and communications on behalf of filing person)

Copy to:

Riccardo A. Leofanti, Esq.

Skadden, Arps, Slate, Meagher & Flom LLP

222 Bay Street, Suite 1750

Toronto, Ontario M5K 1J5

(416) 777-4700

 CALCULATION OF FILING FEE

Transaction Valuation(1)	Amount of Filing Fee(2)
$27,500,000	$1,534.50

(1)	Calculated solely for purposes of determining the amount of the filing fee. This amount is based upon the purchase of 5,392,157 common shares and the maximum tender offer price of $5.10 per common share in cash.
(2)	The amount of the filing fee, calculated in accordance with Rule 0-11 under the Securities Exchange Act of 1934, as amended, equals $55.80 per $1,000,000 of the value of the transaction.

þ Check the box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

Amount Previously Paid:    Form or Registration No.:   Filing Party:   Date Filed:     $1,534.50 Schedule TO Cardiome Pharma Corp. September 1, 2009

o Check the box if filing relates solely to preliminary communications made before the commencement of a tender offer.

Check the appropriate boxes below to designate any transactions to which the statement relates:

o third-party tender offer subject to Rule 14d-1.

þ issuer tender offer subject to Rule 13e-4.

o going-private transaction subject to Rule 13e-3.

o amendment to Schedule 13D under Rule 13d-2.

Check the following box if the filing is a final amendment reporting the results of the tender offer:  o

This Amendment No. 2 amends and supplements the Tender Offer Statement on Schedule TO initially filed on September 1, 2009 (the "Schedule TO"), as amended and supplemented by Amendment No. 1 to the Schedule TO filed on September 18, 2009 ("Amendment No. 1"), in connection with the offer by Cardiome Pharma Corp., a Canadian corporation ("Cardiome" or the "Company"), to purchase a number of its common shares, without par value (the "Shares"), up to an aggregate amount of US$27,500,000 at a price not less than US$4.25 per Share and not more than US$5.10 per Share, net to the seller in cash, without interest, upon the terms and subject to the conditions set forth in the Offer to Purchase, dated September 1, 2009 (the "Offer to Purchase"), the accompanying Issuer Bid Circular (the "Circular"), and the related Letter of Transmittal which, collectively, as amended or supplemented from time to time, constitute the "Tender Offer".  This Amendment No. 2 to the Tender Offer Statement on Schedule TO is intended to satisfy the reporting requirements of Rule 13e-4(c)(2) promulgated under the Securities Exchange Act of 1934, as amended.

All information in the Offer to Purchase and Circular, which was previously filed as Exhibit(a)(1)(A) to the Schedule TO, and the information in Amendment No. 1 is incorporated herein by reference in response to all the items of this Schedule TO, except that such information is hereby amended and supplemented to the extent specifically provided herein.

Items 1 through 11.

Items 1 through 11 of the Schedule TO are amended and supplemented by the Notice of Change and Notice of Variation of the Offer to Purchase (the “Notice”) dated September 25, 2009 and filed as Exhibit (a)(1)(D) hereto. The Notice announces that the Company will extend the term of the Tender Offer until 5:00 p.m. (Eastern time) on October 13, 2009 (the “Extension”), and describes recent developments with respect to the Company and certain amendments to the Offer to Purchase made pursuant to Amendment No. 1. The information set forth in the Notice is incorporated herein by reference. On September 25, 2009, the Company issued press releases announcing (i) the recent developments concerning the Company described in the Notice and (ii) the Extension and that the Company will mail the Notice to its shareholders. The press releases are attached hereto as Exhibit (a)(5)(xiii) and Exhibit (a)(5)(xiv) and the information set forth therein is incorporated herein by reference.

2

Item 12. Exhibits.

Exhibit No.	Description
(a)(1)(A)*	Offer to Purchase, dated September 1, 2009 and the accompanying Issuer Bid Circular.
(a)(1)(B)**	Letter of Transmittal.
(a)(1)(C)**	Notice of Guaranteed Delivery.
(a)(1)(D)	Notice of Change and Notice of Variation of the Offer to Purchase dated September 25, 2009.
(a)(2)	None.
(a)(3)	Not applicable.
(a)(4)	Not applicable.
(a)(5)(i)**	Press release announcing commencement of Tender Offer, dated September 1, 2009.
(a)(5)(ii)***	The Company’s annual information form dated March 26, 2009 for the year ended December 31, 2008 (incorporated by reference to the Company’s Annual Report on Form 40-F for the fiscal year ended December 31, 2008, filed with the United States Securities and Exchange Commission (the “Commission”) on March 30, 2009).
(a)(5)(iii)***	The Company’s audited consolidated financial statements as at and for the years ended December 31, 2008 and 2007, together with the notes thereto and the auditor’s report thereon (incorporated by reference to the Company’s Annual Report on Form 40-F for the fiscal year ended December 31, 2008, filed with the Commission on March 30, 2009).
(a)(5)(iv)***	The Company’s management’s discussion and analysis of our financial condition and results of operation for the years ended December 31, 2008 and 2007 (incorporated by reference to the Company’s Annual Report on Form 40-F for the fiscal year ended December 31, 2008, filed with the Commission on March 30, 2009).
(a)(5)(v)***	The Company’s unaudited interim consolidated financial statements as at and for the six month periods ended June 30, 2009 and 2008 (incorporated by reference to the Company’s Report on Form 6-K furnished to the Commission on August 12, 2009).
(a)(5)(vi)***	The Company’s management’s discussion and analysis of our financial condition and results of operation for the six month period ended June 30, 2009 (incorporated by reference to the Company’s Report on Form 6-K furnished to the Commission on August 12, 2009).
(a)(5)(vii)***	The Company’s material change report dated March 30, 2009 relating to the announcement of financial results for the year ended December 31, 2008 (incorporated by reference to the Company’s Report on Form 6-K furnished to the Commission on March 30, 2009).
(a)(5)(viii)***	The Company’s material change report dated April 20, 2009 relating to the announcement of a collaboration and license agreement with Merck & Co., Inc. for the

3

	development and commercialization of vernakalant, an investigational candidate for the treatment of atrial fibrillation (incorporated by reference to the Company’s Report on Form 6-K furnished to the Commission on April 22, 2009).
(a)(5)(ix)***	The Company’s material change report dated August 11, 2009 relating to the announcement that Douglas G. Janzen has been appointed as Chief Executive Officer and President (incorporated by reference to the Company’s Report on Form 6-K furnished to the Commission on August 11, 2009).
(a)(5)(x)***	The Company’s material change report dated August 11, 2009 relating to the announcement of financial results for the six months ended June 30, 2009 (incorporated by reference to the Company’s Report on Form 6-K furnished to the Commission on August 11, 2009).
(a)(5)(xi)***	The Company’s material change report dated August 12, 2009 related to the announcement of an additional Phase 3clinical trial for vernakalant (iv) (incorporated by reference to the Company’s Report on Form 6-K furnished to the Commission on August 12, 2009).
(a)(5)(xii)***	The Company’s management information circular dated May 18, 2009, distributed in connection with the annual general meeting of shareholders on June 15, 2009 (incorporated by reference to the Company’s Report on Form 6-K furnished to the Commission on May 26, 2009).
(a)(5)(xiii)	Press release announcing recent developments within the Company, dated September 25, 2009.
(a)(5)(xiv)	Press release announcing Notice of Change and Notice of Variation, dated September 25, 2009.
(b)	None.
(d)(1)**	Cardiome Amended Incentive Stock Option Plan.
(g)	None.
(h)	None.

 *     Previously filed with Cardiome’s Schedule TO on September 1, 2009, as amended pursuant to Amendment No. 1 on September 18, 2009.

 **     Previously filed with Cardiome's Schedule TO on September 1, 2009.

 ***     Previously filed with Cardiome's Amendment No. 1 on September 18, 2009.

4

SIGNATURE

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

	/s/ Curtis Sikorsky
Name:	Curtis Sikorsky
Title:	Chief Financial Officer
Date:	September 25, 2009

5

EXHIBIT INDEX

Exhibit No.	Description
(a)(1)(A)*	Offer to Purchase, dated September 1, 2009 and the accompanying Issuer Bid Circular.
(a)(1)(B)**	Letter of Transmittal.
(a)(1)(C)**	Notice of Guaranteed Delivery.
(a)(1)(D)	Notice of Change and Notice of Variation of the Offer to Purchase dated September 25, 2009.
(a)(2)	None.
(a)(3)	Not applicable.
(a)(4)	Not applicable.
(a)(5)(i)**	Press release announcing commencement of Tender Offer, dated September 1, 2009.
(a)(5)(ii)***	The Company’s annual information form dated March 26, 2009 for the year ended December 31, 2008 (incorporated by reference to the Company’s Annual Report on Form 40-F for the fiscal year ended December 31, 2008, filed with the United States Securities and Exchange Commission (the “Commission”) on March 30, 2009).
(a)(5)(iii)***	The Company’s audited consolidated financial statements as at and for the years ended December 31, 2008 and 2007, together with the notes thereto and the auditor’s report thereon (incorporated by reference to the Company’s Annual Report on Form 40-F for the fiscal year ended December 31, 2008, filed with the Commission on March 30, 2009).
(a)(5)(iv)***	The Company’s management’s discussion and analysis of our financial condition and results of operation for the years ended December 31, 2008 and 2007 (incorporated by reference to the Company’s Annual Report on Form 40-F for the fiscal year ended December 31, 2008, filed with the Commission on March 30, 2009).
(a)(5)(v)***	The Company’s unaudited interim consolidated financial statements as at and for the six month periods ended June 30, 2009 and 2008 (incorporated by reference to the Company’s Report on Form 6-K furnished to the Commission on August 12, 2009).
(a)(5)(vi)***	The Company’s management’s discussion and analysis of our financial condition and results of operation for the six month period ended June 30, 2009 (incorporated by reference to the Company’s Report on Form 6-K furnished to the Commission on August 12, 2009).
(a)(5)(vii)***	The Company’s material change report dated March 30, 2009 relating to the announcement of financial results for the year ended December 31, 2008 (incorporated by reference to the Company’s Report on Form 6-K furnished to the Commission on March 30, 2009).

6

(a)(5)(viii)***	The Company’s material change report dated April 20, 2009 relating to the announcement of a collaboration and license agreement with Merck & Co., Inc. for the development and commercialization of vernakalant, an investigational candidate for the treatment of atrial fibrillation (incorporated by reference to the Company’s Report on Form 6-K furnished to the Commission on April 22, 2009).
(a)(5)(ix)***	The Company’s material change report dated August 11, 2009 relating to the announcement that Douglas G. Janzen has been appointed as Chief Executive Officer and President (incorporated by reference to the Company’s Report on Form 6-K furnished to the Commission on August 11, 2009).
(a)(5)(x)***	The Company’s material change report dated August 11, 2009 relating to the announcement of financial results for the six months ended June 30, 2009 (incorporated by reference to the Company’s Report on Form 6-K furnished to the Commission on August 11, 2009).
(a)(5)(xi)***	The Company’s material change report dated August 12, 2009 related to the announcement of an additional Phase 3clinical trial for vernakalant (iv) (incorporated by reference to the Company’s Report on Form 6-K furnished to the Commission on August 12, 2009).
(a)(5)(xii)***	The Company’s management information circular dated May 18, 2009, distributed in connection with the annual general meeting of shareholders on June 15, 2009 (incorporated by reference to the Company’s Report on Form 6-K furnished to the Commission on May 26, 2009).
(a)(5)(xiii)	Press release announcing recent developments within the Company, dated September 25, 2009.
(a)(5)(xiv)	Press release announcing Notice of Change and Notice of Variation, dated September 25, 2009.
(b)	None.
(d)(1)**	Cardiome Amended Incentive Stock Option Plan.
(g)	None.
(h)	None.

*  Previously filed with Cardiome’s Schedule TO on September 1, 2009, as amended pursuant to Amendment No. 1 on September 18, 2009.

**  Previously filed with Cardiome's Schedule TO on September 1, 2009.

*** Previously filed with Cardiome's Amendment No. 1 on September 18, 2009.

EX-99

Exhibit (a)(1)(D)

This document is important and requires your immediate attention. If you are in any doubt as to how to deal with it, you should consult your investment dealer, stock broker, bank manager, lawyer, accountant or other professional advisor.

NOTICE OF CHANGE AND NOTICE OF VARIATION

by

of its

OFFER TO PURCHASE FOR CASH

up to US$27.5 million of its Common Shares without par value at a Purchase Price of

Not Less Than US$4.25 and Not More Than US$5.10 per Common Share

Cardiome Pharma Corp. (“Cardiome” or the “Company”) hereby gives notice to the holder of its common shares that it has amended its offer to purchase (the “Original Offer to Purchase”) and the accompanying issuer bid circular (the “Original Circular”), each dated September 1, 2009, pursuant to which Cardiome invited the holders of its common shares to deposit, for purchase and cancellation by the Company, common shares of the Company in order to (i) extend the period during which the Offer is open for acceptance to 5:00 p.m. (Eastern time) on October 13, 2009, unless further extended or withdrawn by the Company, and (ii) update certain information disclosed in the Original Offer to Purchase and Original Circular to reflect certain changes in information and other recent developments.

THIS OFFER HAS BEEN EXTENDED AND IS NOW OPEN FOR ACCEPTANCE UNTIL 5:00 P.M. (EASTERN TIME) ON OCTOBER 13, 2009 (THE “EXPIRATION DATE”), UNLESS FURTHER EXTENDED OR WITHDRAWN BY THE COMPANY.

In this Notice of Change and Notice of Variation (the “Notice”), references to the “Offer to Purchase” shall refer to the Original Offer to Purchase, as amended by this Notice, and references to the “Circular” shall refer to the Original Circular, as amended by this Notice. The Offer to Purchase, the Circular and the related Letter of Transmittal together constitute the “Offer”.

Unless the context requires otherwise or unless otherwise defined, defined terms used in this Notice have the same meaning as in the Original Offer to Purchase and the Original Circular. This Notice should be read in conjunction with the Original Offer to Purchase and Original Circular, and the related Letter of Transmittal and Notice of Guaranteed Delivery. Except as otherwise set forth in this Notice, the terms and conditions of the Offer previously set forth in the Original Offer to Purchase and Original Circular, and the related Letter of Transmittal, continue to be applicable in all respects.

If you have validly deposited and not withdrawn your common shares, you do not need to take any further action to accept the Offer.  If you have not tendered your common shares to the Offer and wish to do so, you must either:

· deliver the certificate representing your common shares in proper form for transfer, together with a properly completed and duly executed Letter of Transmittal (or a manually executed photocopy) with signature guarantees, if required as described under Section 5 of the Original Offer to Purchase, “Procedure for Depositing Shares – Signature Guarantees”, and any other documents required by the Letter of Transmittal, to the Depository at one of the addresses listed in the Letter of Transmittal before the Offer expires;

· if you cannot deliver the required documents to the Depository before the Offer expires, follow the guaranteed delivery procedures described under Section 5 of the Original Offer to Purchase, “Procedure for Depositing Shares – Guaranteed Delivery” before the Offer expires; or

· if your common shares are held in the book-entry system, deposit your common shares in accordance with the procedures described under Section 5 of the Original Offer to Purchase, “Procedure for Depositing Shares – Book Entry Transfer Procedures” before the Offer expires.

September 25, 2009

Questions and requests for assistance may be directed to the Dealer Managers, in each case at the telephone numbers and addresses set forth on the back cover of this Notice. See Section 5 of the Original Offer to Purchase, “Procedure for Depositing Shares” and the instructions to the related Letter of Transmittal for instructions on how to deposit your common shares.  See Section 6 of the Original Offer to Purchase, “Withdrawal Rights” for instructions on how to withdraw your common shares.

No broker, dealer or other person has been authorized to give any information or make any representation on behalf of the Company other than as contained in the Offer, and, if any such information or representation is given or made, it must not be relied upon as having been authorized by the Company.

This document does not constitute an offer or a solicitation to any person in any jurisdiction in which such offer or solicitation is unlawful. The Offer is not being made to, and deposits will not be accepted from or on behalf of shareholders in any jurisdiction in which the making or acceptance thereof would not be in compliance with the laws of such jurisdiction. However, Cardiome may, in its sole discretion, take such action as it may deem necessary to extend the Offer to shareholders in any such jurisdiction.

FORWARD-LOOKING STATEMENTS

This Notice and the information in the Original Offer to Purchase and the Original Circular may contain statements that constitute “forward-looking information” or “forward-looking statements” within the meaning of Canadian securities laws. See the “Cautionary Statement for Forward-Looking Statements” in the Offer to Purchase.

GENERAL MATTERS

In this Notice, “Cardiome”, the “Company”, “we”, “us” or “our” refer collectively to Cardiome Pharma Corp. and its consolidated subsidiaries and “common shares” means our common shares without par value, in each case unless the context otherwise requires.

2

NOTICE OF CHANGE AND NOTICE OF VARIATION

September 25, 2009

To the Shareholders of Cardiome Pharma Corp.

By notice to the Depository, and as set forth in this Notice, we have (i) extended the period during which the Offer is open for acceptance to 5:00 p.m. (Eastern time) on October 13, 2009, unless further extended or withdrawn by us, and (ii) updated certain information disclosed in the Original Offer to Purchase and Original Circular to reflect certain changes in information and other recent developments.

Unless the context requires otherwise or unless otherwise defined, capitalized terms used in this Notice have the same meaning as in the Original Offer to Purchase and the Original Circular. This Notice should be read in conjunction with the Original Offer to Purchase and Original Circular, and the related Letter of Transmittal. Except as otherwise set forth in this Notice, the terms and conditions of the Offer previously set forth in the Original Offer to Purchase and Original Circular, and the related Letter of Transmittal, continue to be applicable in all respects.

Shareholders are urged to consider carefully the income tax consequences of accepting the Offer. Shareholders should consult their own tax advisors as to the specific tax consequences to them of accepting the Offer. See Section 15 of the Original Circular, “Income Tax Considerations”.

1. Extension of the Offer

We have amended the Offer by extending the period during which the Offer is open for acceptance from 5:00 p.m. (Eastern time) on October 6, 2009 to 5:00 p.m. (Eastern time) on October 13, 2009. Accordingly, all references to the “Expiration Date” in the Offer to Purchase and the Circular, and the related Letter of Transmittal and Notice of Guaranteed Delivery, shall hereafter be references to October 13, 2009 or such later date to which we may extend the Offer.

2. Change in Information Contained in the Original Offer to Purchase and Original Circular

Development Strategy for GED-aPC Technology and Transition of Dr. Charles Fisher to Consulting Role

On September 25, 2009, we announced that future development and commercialization of our GED-aPC technology, currently held in a subsidiary company, will be funded externally. In support of the transition of our GED-aPC program, Dr. Charles Fisher, our Chief Medical Officer and Executive Vice President, Clinical & Regulatory Affairs, will assume an advisory role as a consultant to us, effective October 1, 2009. If the GED-aPC subsidiary seeks external capital to fund future activities, we may choose to co-invest in the venture to maintain our equity interest.

In November 2007, we initiated subject dosing in a Phase 1 study of GED-aPC, and successfully completed multiple cohorts.  We have determined that no further cohorts will be conducted, and enrollment in this trial is complete.  The single-blinded, placebo-controlled, dose-ranging study measured the safety, tolerability, pharmacokinetics and pharmacodynamics of GED-aPC in 48 healthy subjects, with each subject receiving a 15-minute loading dose at the start of a 24-hour continuous intravenous infusion of GED-aPC. Results from this study are expected to be released by the end of 2009.

Comments from the U.S. Securities Exchanges Commission (the “Commission”)

Pursuant to comments received from the Commission on September 15, 2009, we filed an Amendment No. 1 to Schedule TO relating to the Offer on September 18, 2009.  Amendment No. 1 to Schedule TO is available on the Commission's website at www.sec.gov. The following is a summary of the amendments made to the Original Offer to Purchase pursuant to Amendment No. 1 to Schedule TO:

· The “Cautionary Statement Regarding Forward-Looking Statements” on page iv of the Original Offer to Purchase was amended to remove the reference to the United States Private Securities Litigation reform Act of 1995;

· The “Summary Term Sheet” and Section 6,  “Withdrawal Rights” of the Original Offer to Purchase were amended to allow a withdrawal right if we do not accept the common shares for payment within forty business days after the commencement of the Offer;

3

· Section 7, “Conditions of the Offer” of the Original Offer to Purchase was amended to limit our ability to terminate the Offer under certain conditions only up to the expiry of the Offer rather than at any time before the payment of any common shares; and

· Section 7, “Conditions of the Offer” of the Original Offer to Purchase was amended to note that the termination right regarding the commencement of war or armed hostilities includes only a “material escalation” of any such war or armed hostility that Canada or the United States are currently engaged in.

3. Time and Manner of Acceptance of the Offer

The Offer is open for acceptance until 5:00 p.m. (Eastern time) on October 13, 2009, unless further extended or withdrawn by us. The procedure for accepting the Offer is described in Section 5 of the Original Offer to Purchase, “Procedure for Depositing Shares”.

4. Taking Up and Payment for Deposited Shares

Subject to the terms and conditions of the Offer (as the same may be amended), including conditions relating to pro-ration and conditional tenders, and subject to and in accordance with applicable Canadian and U.S. securities laws, we will take up and pay for all common shares properly deposited or deemed to be deposited for purchase (and not withdrawn) at or below the Purchase Price promptly after the Offer expires. The procedure by which we will take up and pay for common shares tendered to the Offer is described in Section 9 of the Offer to Purchase, “Taking Up and Payment for Deposited Shares”.

5. Withdrawal of Shares

Common shares deposited for purchase under the Offer may be withdrawn from the Offer in accordance with the provisions set forth in Section 6 of the Offer to Purchase, “Withdrawal Rights”.

6. Amendments to Offering Documents

The Original Offer to Purchase and the Original Circular, and the related Letter of Transmittal and Notice of Guaranteed Delivery, are hereby amended to the extent necessary to reflect the information contained in this Notice.

7. Statutory Rights

Securities legislation of the provinces and territories of Canada provides shareholders with, in addition to any other rights they may have at law, one or more rights of rescission, price revision or to damages if there is a misrepresentation in a circular or notice that is required to be delivered to those shareholders. However, such rights must be exercised within prescribed time limits. Shareholders should refer to the applicable provisions of the securities legislation of their province or territory for particulars of those rights or consult a lawyer.

September 25, 2009

4

CERTIFICATE

September 25, 2009

The Board of Directors of Cardiome Pharma Corp. (“Cardiome”) has approved the contents of the Notice of Change and Notice of Variation of Cardiome dated September 25, 2009 and the delivery thereof to the shareholders. The foregoing, together with the Original Offer to Purchase and the Original Circular, each dated September 1, 2009, contains no untrue statement of a material fact and does not omit to state a material fact that is required to be stated or that is necessary to make a statement not misleading in the light of the circumstances in which it was made.

(Signed) Douglas G. Janzen Chief Executive Officer and President	(Signed) Curtis Sikorsky Chief Financial Officer
On behalf of the Board of Directors:
(Signed) Harold H. Shlevin Director	(Signed) Peter W. Roberts Director

C-1

DEPOSITORY FOR THE OFFER

The Letter of Transmittal or, if applicable, the Notice of Guaranteed Delivery, the certificates for common shares and any other required documents must be sent or delivered by each depositing shareholder or the shareholder’s broker, commercial bank, trust company or other nominee to the Depository at one of its addresses specified below:

Computershare Investor Services Inc.

By Mail: PO Box 7021 31 Adelaide Street East Toronto, Ontario  M5C 3H2 Attention:  Corporate Actions International Calls: 1-514-982-7555 Toll Fee Number: 1-800-564-6253 By Hand or Overnight Courier: 100 University Avenue, 9th Floor Toronto, Ontario  M5J 2Y1 Attention:  Corporate Actions

Any questions or requests for assistance may be directed to the Depository at the addresses and telephone number specified above. Shareholders also may contact the Dealer Managers or their broker, commercial bank or trust company for assistance concerning the Offer. Manually executed photocopies of the Letter of Transmittal or the Notice of Guaranteed Delivery will be accepted.

THE DEALER MANAGERS FOR THE OFFER ARE:

In the United States:   Oppenheimer & Co. Telephone:  (212) 667-5506 In Canada:   Canaccord Capital Corporation Telephone:  (416) 869-3349

EX-99

Exhibit (a)(5)(xiii)

	6190 Agronomy Road, 6th Floor	Tel: 604-677-6905
	Vancouver, B.C.	Fax: 604-677-6915
	V6T 1Z3

FOR IMMEDIATE RELEASE    NASDAQ: CRME   TSX: COM

CARDIOME ANNOUNCES NEXT STEPS FOR GED-APC

ASSET AND TRANSITION OF DR. CHARLES FISHER TO

CONSULTING ROLE

Vancouver, Canada, September 25, 2009 -- Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced the decision that future development and commercialization of its GED-aPC technology, currently held in a subsidiary company, will be funded externally from Cardiome.  In support of the transition of the GED-aPC program, Dr. Charles Fisher, Chief Medical Officer and Executive Vice President, Clinical & Regulatory Affairs, will assume an advisory role as a consultant to Cardiome, effective October 1, 2009.  It is expected that the GED-aPC subsidiary will seek external capital to fund future activities.  Cardiome may choose to co-invest in the venture to maintain its equity interest.

“We want to thank Dr. Fisher for the pivotal role he has played at Cardiome during his tenure, and we look forward to him continuing to support our programs and partners as a consultant, along with being integral to our strategy around GED-aPC,” stated Doug Janzen, President and Chief Executive Officer of Cardiome.  “We continue to believe that GED-aPC has the potential to be effective in treating a variety of diseases, and next steps for the program will be focused on finding external investors and/or partners to assist in future development of the asset.  We believe that bringing other sources of capital and expertise into this collaboration will be the best thing for the program and our shareholders.”

“I have had the privilege over the past five years of working with an incredibly talented and dedicated team at Cardiome, and I am proud of the role I have played in the development of the group.  I look forward to continuing to support Cardiome and our partners Merck and Astellas in my role as a consultant,” stated Dr. Fisher.  “I have extensive experience with the GED-aPC program, and Cardiome and I have confidence that a business can be built and capital can be raised to allow this asset to reach its full potential.”

In November 2007, Cardiome initiated subject dosing in a Phase 1 study of GED-aPC, and successfully completed multiple cohorts.  Cardiome has determined that no further cohorts will be conducted, and enrollment in this trial is complete.  The single-blinded, placebo-controlled, dose-ranging study measured the safety, tolerability, pharmacokinetics and pharmacodynamics of GED-aPC in 48 healthy subjects, with each subject receiving a 15-minute loading dose at the start of a 24-hour continuous intravenous infusion of GED-aPC.  Results from this study are expected to be released by the end of 2009.

GED-aPC is an engineered analog of recombinant human activated Protein C (aPC) with enhanced cytoprotective, anti-inflammatory, anti-thrombotic and strong binding to endothelial protein C receptor properties, and has broad potential across multiple indications.  Cardiome acquired exclusive worldwide rights for GED-aPC for all indications in April 2007.

About Cardiome Pharma Corp.

Cardiome Pharma Corp. is a product-focused drug development company dedicated to the advancement and commercialization of novel treatments for disorders of the heart and circulatory system.  Cardiome is traded on the NASDAQ National Market (CRME) and the Toronto Stock Exchange (COM).  For more information, please visit our web site at www.cardiome.com.

For Further Information:

Peter K. Hofman

Senior Director, Investor Relations

(604) 676-6993 or Toll Free: 1-800-330-9928

Email: phofman@cardiome.com

Forward-Looking Statement Disclaimer

Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect” and similar expressions.  Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments expressed or implied by such forward-looking statements or information.  Such factors include, among others, our stage of development, lack of product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing.  Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: we may not be able to successfully develop and obtain regulatory approval for vernakalant (iv) or vernakalant (oral) in the treatment of atrial fibrillation or any other current or future products in our targeted indications; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and sales capabilities and the costs of launching our products may be greater than anticipated; we rely on third parties for the continued supply and manufacture of vernakalant (iv) and vernakalant (oral) and we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Securities and Exchange Commission available at www.sec.gov and the Canadian securities regulatory authorities at www.sedar.com.  Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement.  All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.

EX-99

Exhibit (a)(5)(xiv)

	6190 Agronomy Road, 6th Floor	Tel: 604-677-6905
	Vancouver, B.C.	Fax: 604-677-6915
	V6T 1Z3

FOR IMMEDIATE RELEASE    NASDAQ: CRME   TSX: COM

CARDIOME PHARMA CORP. ANNOUNCES NEW

EXPIRATION DATE FOR TENDER OFFER

Vancouver, Canada, September 25, 2009 – Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) (“Cardiome” or the “Company”) announced that it will extend the term of its modified “Dutch Auction” tender offer (the “Offer”) for up to US$27.5 million of its common shares commenced on September 1, 2009. The Offer, which was initially schedule to expire at 5:00 p.m. (Eastern time) on October 6, 2009, has been extended until 5:00 p.m. (Eastern time) on October 13, 2009, unless further extended or withdrawn by the Company.

Cardiome is extending the Offer in order to amend the offer to purchase and issuer bid circular (as amended, the “Offer to Purchase and Circular”) in order to include information about its development strategy for GED-aPC and the related transition of Dr. Charles Fisher, Chief Medical Officer and Executive Vice President, Clinical & Regulatory Affairs, to a consulting role. A separate press release regarding the Company’s development strategy and the transition of Dr. Fisher to a consulting role has been filed by the Company. Cardiome will mail a notice of change and variation (the “Notice”) to its shareholders today, setting out the new expiration date of the Offer and the change in information in the Offer to Purchase and Circular. The Notice is being filed concurrently with the securities regulatory authorities in the United States and Canada.

The tender offer will be conducted as a modified “Dutch auction”, which will enable shareholders to select a price between US$4.25 per share and US$5.10 per share at which they are willing to tender their common shares to the offer. The purchase price will be the lowest price per share between US$4.25 and US$5.10 that enables Cardiome to purchase US$27.5 million of common shares. For further details on the terms and conditions of the Offer, please consult the Offer to Purchase and Circular, as amended by the Notice.

Press release is for informational purposes only

This press release is for informational purposes only and does not constitute an offer to buy or the solicitation of an offer to sell Cardiome’s common shares. The solicitation and the offer to buy Cardiome’s common shares is being made only pursuant to the Offer to Purchase and Circular, as amended by the Notice, and related documents. Cardiome has filed the Offer to Purchase and Circular and related documents with the Canadian securities regulatory authorities and a Tender Offer Statement on Schedule TO with the United States Securities and Exchange Commission (the “SEC”). Shareholders should carefully read the Tender Offer Statement, as amended, the Offer to Purchase and Circular, as amended by the Notice, and the related letter of transmittal and other related documents prior to making any decision with respect to the Offer because they contain important information, including the various terms and conditions of the offer.  The Notice will be delivered without charge to all holders of Cardiome’s common shares.

The Tender Offer Statement, as amended, is available without charge at the SEC website at www.sec.gov or by calling the Corporate Secretary of Cardiome at (604) 676-6993. The Offer to Purchase and Circular, as amended by the Notice, and the related letter of transmittal and all other offer documents that are required to be filed in Canada are also available without charge at www.sedar.com.

About Cardiome Pharma Corp.

Cardiome Pharma Corp. is a product-focused drug development company dedicated to the advancement and commercialization of novel treatments for disorders of the heart and circulatory system.  Cardiome is traded on the NASDAQ Global Market (CRME) and the Toronto Stock Exchange (COM).  For more information, please visit our web site at www.cardiome.com.

For Further Information:

Peter K. Hofman

Senior Director, Investor Relations

(604) 676-6993 or Toll Free: 1-800-330-9928

Email: phofman@cardiome.com

Forward-Looking Statement Disclaimer

Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect” and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments expressed or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: we, together with our collaborative partners, may not be able to successfully develop and obtain regulatory approval for vernakalant (iv) or vernakalant (oral) in the treatment of atrial fibrillation or any other current or future products in our targeted indications; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and sales capabilities and the costs of launching our products may be greater than anticipated; we rely on third parties for the continued supply and manufacture of vernakalant (iv) and vernakalant (oral) and we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Securities and Exchange Commission available at www.sec.gov and the Canadian securities regulatory authorities at www.sedar.com. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.